FindTrial
Sign In

study of correlation between Level dynamic change of plasma soluble programmed cell death ligand 1 at diagnosis and post-treatment with prognosis in patients of Diffuse large B-cell lymphoma

study of correlation between Level dynamic change of plasma soluble programmed cell death ligand 1 at diagnosis and post-treatment with prognosis in patients of Diffuse large B-cell lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DCD-15006679
Enrollment
Unknown
Registered
2015-06-30
Start date
2015-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B-cell lymphoma

Interventions

Gold Standard:
Index test:

Sponsors

Hematology Department of Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. To be aged from 18 years to 80 years; 2. A biopsy proven diagnosis of DLBCL according to the current WHO criteria by 2 pathologist; 3. Life expectancy more than 4 months; 4. Non previously treated; 5. HIV negative, HBs negative, HCV negative; 6. Signed informed consent obtained.

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. Signed informed consent not obtained; 3. Preliminary treatment; 4. HIV positive, HBs positive, HCV positive.

Design outcomes

Primary

MeasureTime frame
overall survival;progress free survival;—

Secondary

MeasureTime frame
Overall Response Rate;—

Countries

China

Contacts

Public ContactDaobin Zhou
daobinzhou@yahoo.com+86 13901113623

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026